Online Thinking-Style Training for Pain in Type 2 Diabetes
Tests online training that teaches calmer readings of situations in adults with diabetes and pain.
Plain-language title generated from the registry record
Registry title: Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain
Key facts
- Where
- Camperdown, AustraliaSee the site
Where in Australia
- University of SydneyCamperdown, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Sydney
- Trial code
- NCT06908486
- Record updated
- 2 June 2025
- Original description
The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question[s] it aims to answer is whether interpretation bias training away from pain improves pain outcomes.Read full original descriptionShow less
Assessing Cognitive Bias Modification for Interpretation (CBM-I) on Pain Severity and Interference in People With Type 2 Diabetes and Persistent Pain
The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question[s] it aims to answer is whether interpretation bias training away from pain improves pain outcomes.
Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up.
The study hypothesises that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.
Inclusion: Over 18 years of age; Have a diagnosis of Type 2 diabetes; Have persistent pain (pain present on more days than not, for 3 months or longer); Score ≥ 3 on average pain severity on the Brief Pain Inventory (BPI); Fluent in English; Have access to internet and ability to use a computer over a three month period.
Exclusion: No diagnosis of Type 2 diabetes; Under 18 years of age; No persistent pain; Not fluent in English; No access to internet nor ability to use a computer.